<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157116</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00004682</org_study_id>
    <nct_id>NCT02157116</nct_id>
  </id_info>
  <brief_title>Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Dose-Dense Induction/Neoadjuvant Chemotherapy in the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer With Additional Genomic Analyses to Identify Signatures Predictive of Chemotherapy Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less
      time between treatments than in standard chemotherapy. The two chemotherapy drugs used in
      this study, docetaxel and cisplatin, are approved for the treatment of lung cancer when given
      every 21 days. This study is exploring the response to chemotherapy when these drugs are
      given every 14 days. In addition, genetic tests will be performed on pre-treatment specimens
      to identify signatures that may predict chemotherapy sensitivity or resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive induction chemotherapy with cisplatin and docetaxel. Pegfilgrastim
      will be administered approximately 24 hours following the end of the day 1 chemotherapy
      infusion. Cycles will be repeated every 2 weeks for 3 cycles. Patients deemed to be
      resectable will undergo surgical resection followed by postoperative thoracic radiotherapy.
      Patients deemed inoperable will additionally receive concurrent chemoradiotherapy. Response,
      using radiographic and/or pathologic means, will identify two cohorts; responders and
      nonresponders.Gene expression profiling will then be performed on pre-treatment specimens to
      identify signatures that predict for chemotherapy sensitivity or resistance.

      The target enrollment is 45 patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient accrual to meet analysis goals
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Response</measure>
    <time_frame>Between 2 and 3 weeks after induction</time_frame>
    <description>Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Response is defined as the number patients with a Complete Response (CR), disappearance of all target lesions, or a Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy</measure>
    <time_frame>at the end of the study, estimated 2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Grade III/IV Hematologic Adverse Events</measure>
    <time_frame>During induction chemotherapy, approximately 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Grade III/IV Non-hematologic Adverse Events</measure>
    <time_frame>During induction chemotherapy, approximately 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Able to Maintain Hemoglobin Between 11-13 g/dL During Induction</measure>
    <time_frame>During induction, approximately 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Induction Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Induction Chemotherapy</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Induction Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>Induction Chemotherapy</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with documented stage III NSCLC (IIIA or IIIB, without malignant
             pleural/pericardial effusion) are eligible for enrollment if they are considered
             appropriate for treatment with chemotherapy, radiation, or surgery;

          -  IIIA: T1-3 N2 M0, T3 N1 M0

          -  IIIB: T4 N0-2 M0, T 1-4 N3 M0

          -  Measurable or evaluable disease

          -  Previously untreated with chemotherapy or radiotherapy for lung cancer;

          -  No brain metastases;

          -  No prior XRT

          -  Performance status 0-2

          -  ≥18 years of age

          -  Informed Consent

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

          -  Platelets ≥ 100 x 109/L

          -  Bilirubin ≤ 1.5 x upper limit of normal for the institution (ULN)

          -  SGOT and SGPT ≤ 2.5 x ULN for the institution

          -  Creatinine ≤ 1.6 mg/dL

          -  Hemoglobin ≥ 8.0 g/dL

          -  Peripheral neuropathy ≤ grade 1

        Exclusion Criteria:

          -  Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN® insulin,
             L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A);

          -  Use of IV systemic antibiotics within 72 hours prior to chemotherapy;

          -  Known HIV infection

          -  Lithium or cytokines within 2 weeks prior of entry

          -  Additional concurrent investigational drugs

          -  History of myelodysplastic syndrome

          -  Pregnant, nursing or having unprotected sex

          -  Not available for follow-up assessment

          -  Unable to comply with protocol procedures

          -  Illnesses that may compromise ability to give informed consent.

          -  Patients with a history of severe hypersensitivity reaction to Taxotere® or other
             drugs formulated with polysorbate 80.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <results_first_submitted>June 5, 2014</results_first_submitted>
  <results_first_submitted_qc>June 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-Dense Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened to enrollment in May 2006 and closed in October 2009 due to failure to meet accrual goals for data analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>All subjects who signed a consent form are included, whether or not they received treatment as a part of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">signed consent form</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Screening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects who signed a consent form are included, whether or not they received treatment as a part of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction Response</title>
        <description>Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Response is defined as the number patients with a Complete Response (CR), disappearance of all target lesions, or a Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions.</description>
        <time_frame>Between 2 and 3 weeks after induction</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Induction Response</title>
          <description>Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Response is defined as the number patients with a Complete Response (CR), disappearance of all target lesions, or a Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions.</description>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy</title>
        <time_frame>at the end of the study, estimated 2.5 years</time_frame>
        <population>Due to insufficient accrual, gene analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy</title>
          <population>Due to insufficient accrual, gene analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade III/IV Hematologic Adverse Events</title>
        <time_frame>During induction chemotherapy, approximately 6 weeks</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade III/IV Hematologic Adverse Events</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade III/IV Non-hematologic Adverse Events</title>
        <time_frame>During induction chemotherapy, approximately 6 weeks</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade III/IV Non-hematologic Adverse Events</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Able to Maintain Hemoglobin Between 11-13 g/dL During Induction</title>
        <time_frame>During induction, approximately 6 weeks</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Able to Maintain Hemoglobin Between 11-13 g/dL During Induction</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Approximately 10 years</time_frame>
        <population>Due to insufficient accrual, the study was stopped prior to completing the 10 year followup for survival.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Due to insufficient accrual, the study was stopped prior to completing the 10 year followup for survival.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treated Patients</title>
          <description>Due to insufficient accrual, adverse event data was not analyzed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Riedel, MD</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-6932</phone>
      <email>richard.riedel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

